Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance

An adjuvanted recombinant zoster vaccine (RZV) is licensed for the prevention of herpes zoster. This paper reviews its safety and reactogenicity. A pooled analysis of two pivotal randomized Phase-3 trials (NCT01165177, NCT01165229) in adults ⩾50 years found that more solicited adverse events (AEs) w...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiore, Joseph, Co-van der Mee, Maribel Miranda, Maldonado, Andrés, Glasser, Lisa, Watson, Phil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734271/
https://www.ncbi.nlm.nih.gov/pubmed/35005428
http://dx.doi.org/10.1177/25151355211057479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734271/
https://www.ncbi.nlm.nih.gov/pubmed/35005428
http://dx.doi.org/10.1177/25151355211057479

Ejemplares similares